NEW YORK, December 12, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Perrigo Co. (NYSE: PRGO), Thermo Fisher Scientific, Inc. (NYSE: TMO), Endo Health Solutions Inc. (NASDAQ: ENDP), Waters Corp. (NYSE: WAT), and Keryx Biopharmaceuticals Inc. (NASDAQ: KERX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Perrigo Co. Research Report
On December 9, 2013, Perrigo Co.'s (Perrigo) stock declined 0.72%, ending the day at $154.51. Over the previous three trading sessions, shares of Perrigo declined 0.25% compared to the Dow Jones Industrial Average which increased 0.85% during the same period. The Full Research Report on Perrigo Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Thermo Fisher Scientific, Inc. Research Report
On December 4, 2013, Thermo Fisher Scientific, Inc. (Thermo Fisher Scientific) reported that it finalized the pricing for its previously declared offering of senior notes, which include: $900 million aggregate principal amount of 1.30% senior notes due 2017 at an issue price of 99.941% of the principal amount; $900 million aggregate principal amount of 2.40% senior notes due 2019 at an issue price of 99.796% of the principal amount; $1 billion aggregate principal amount of 4.15% senior notes due 2024 at an issue price of 99.73% of the principal amount; and $400 million aggregate principal amount of 5.30% senior notes due 2044 at an issue price of 99.928% of the principal amount. The Company informed that subject to customary closing conditions, the issuance of the notes is slated to conclude on December 11, 2013, and the notes will provide interest on a semi-annual basis. Thermo Fisher Scientific intends to utilize the proceeds of the offering to pay for a portion of its acquisition of Life Technologies Corporation. The Full Research Report on Thermo Fisher Scientific, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Endo Health Solutions Inc. Research Report
On December 9, 2013, American Medical Systems® Inc. (AMS), a subsidiary of Endo Health Solutions Inc. (Endo), reported that it has received FDA 510(k) Clearance of its RetroArc™ Retropubic Sling System for treatment of female stress urinary incontinence (SUI). The Company informed that the said system was developed with the help of leading physicians, and it preserves familiar features of transvaginal retropubic sling systems while combining new improvements and the capacity to make fine-tuned adjustments to address the needs of physicians. Steve Blum, AMS General Manager of Women's Health, commented, "FDA Clearance of the RetroArc Retropubic Sling System rounds out the AMS family of slings. It underscores our commitment to physicians and patients for the treatment of female stress urinary incontinence, and builds on our leadership in Women's Health." Camille Farhat, AMS President, added, "At AMS, we are committed to providing world-class medical devices that improve patients' quality of life. The RetroArc Retropubic Sling System is another example of how AMS innovates to provide world-class medical devices for patients around the world. We support our products with robust physician training and we encourage physician-patient conversations on the risks and benefits of these therapies." The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Waters Corp. Research Report
On December 9, 2013, Waters Corp. (Waters) reported that John Ornell, its Chief Financial Officer, announced his intention to transition to a reduced workload and resign as the Company's Chief Financial Officer - both announcements will take effect on February 1, 2014. Waters informed that Ornell will then continue to serve the Company in an advisory capacity on a part-time basis. The Company further reported that its Board of Directors has elected Eugene G. Cassis, currently acting as Corporate Vice President of Worldwide Business Development and Investor Relations, as the Company's interim Chief Financial Officer, effective February 1, 2014. Douglas A. Berthiaume, Chairman and CEO, commented, "I'd like to thank John for his dedication to Waters over the past 23 years and for his many contributions as the Company's CFO for the past 12 years. I am pleased that Gene Cassis will serve the Company as interim CFO. Gene brings a wealth of relevant experience and a record of success in key leadership positions while already enjoying close working relationships with our investor base, our banking contacts and with Waters Executive Committee." The Full Research Report on Waters Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Keryx Biopharmaceuticals Inc. Research Report
On December 9, 2013, Keryx Biopharmaceuticals Inc.'s (Keryx) stock declined 1.25%, ending the day at $12.59. Over the previous three trading sessions, shares of Keryx declined 14.24% compared to the Nasdaq Composite which increased 0.76% during the same period. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner